Trial · NCT04941911
A Feasibility Study of Octreotide Infusion During Liver Transplant.
NCT04941911, Phase 2, Unknown, University College, London
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Feasibility Study of Octreotide Infusion During Liver Transplant. Trials, record NCT04941911. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04941911
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Feasibility Study of Octreotide Infusion During Liver Transplant.
- NCT number
- NCT04941911
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- University College, London
- Conditions
- Liver Transplantation, Renal Failure
- Interventions
- Octreotide Acetate, Placebo
- First posted
- 2021-06-28
- Last updated
- 2023-05-03
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Ability to recruit patients. | Approximately 180 days. | This will be assessed by: • Ability to recruit patients (target: ≥ 30% consent rate of eligible patients admitted for transplant) |
| Primary | Completion of the study intervention. | Approximately 9.5 hours. | This will be assessed by: • The percentage of patients successfully completing the study intervention. Defined as eligible patients who receive the entire study drug infusion in a blinded manner. |
| Secondary | The incidence of acute kidney injury. | Within 24, 72 and 168 hours post-operatively. | This will be defined by Acute Kidney Injury Network stage 1 criteria (a 50% increase in serum creatinine from baseline or less than 0.5 ml/kg/hr urine output for 6-12 hours post-transplant). |
| Secondary | Post-operative incidence of a new requirement for renal replacement therapy. | Within 24 hours, 72 hours, one and two weeks post-operatively. | Administration of haemofiltration or haemodiafiltration. |
| Secondary | Incidence of new chronic kidney disease or deterioration of chronic kidney disease. | At thirty and ninety days post operative. | This is defined as a new persistent estimated glomerular filtration rate below 60 ml/min/1.73m2 or a decline in pre-existing glomular function to a more severe KDIGO chronic kidney disease. status. |
| Secondary | Incidence of early allograft dysfunction. | At day seven post-operatively | Early allograft dysfunction defined by the presence of one or more of the following: total bilirubin ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST \> 2,000 IU/L within the first 7 days post-operatively. |
| Secondary | Patient mortality. | At thirty and ninety days post-operatively. | Patient mortality at thirty and ninety days post-operatively. |
| Secondary | Intra-operative red blood cell salvage. | Within 24, 72 and 168 hours post-operatively. | Total volume of intra-operative red blood cell salvage available for reinfusion following washing and centrifugation. |
| Secondary | Volume of packed red blood cell transfusion. | Intra-operatively and at 24, 72 and 168 hours post-operatively. | Volume of packed red blood cell transfusion administered intra-operatively and at 24, 72 and 168 hours post-operatively. |
| Secondary | Incidence of adverse events secondary to study drug infusion. | Intra-operatively and up to 24 hours post-operatively. | Recorded adverse events are: abnormal QTc interval (460ms in men, 470ms in women) or associated ventricular arrhythmia or Torsades de Pointes, unexpected or resistant hypoglycaemia (blood sugar \< 4mM) and clinical suspicion of allergic or anaphylactic reaction. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04941911
GET https://conductscience.org/api/trials/v1/NCT04941911/registered